drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
An allogeneic, off-the-shelf CD70-directed CAR T-cell therapy (UCAR-T). Gene-engineered T cells express a chimeric antigen receptor targeting CD70 to activate T-cell signaling (CD3ζ and costimulatory domains), leading to cytokine release and cytolytic elimination of CD70-positive tumor cells and modulation of the CD70–CD27 axis.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic (off-the-shelf) T cells are gene-engineered to express a CD70-directed chimeric antigen receptor. Upon binding CD70 on tumor cells, CAR signaling (CD3zeta with costimulatory domains) activates T-cell effector functions, leading to cytokine release and targeted cytolytic killing of CD70-positive cells and modulation of the CD70–CD27 axis, independent of the native T-cell receptor.
drug_name
CHT101
nct_id_drug_ref
NCT06730659